{"entity":{"type":"insider","cik":"0001780113","url":"/insider/0001780113","json_url":"/insider/0001780113.json","name":"Harris Erik","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":19,"n_filings":16,"first":"2020-10-16","last":"2026-03-03","span_basis":"filed_date"},"name_variants":[{"name":"Harris Erik","source":"filing","n_filings":16,"first_seen":"2020-10-16","last_seen":"2026-03-03"}],"transactions":[{"id":5884084,"accession":"0001193125-26-089282","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-089282","line_url":"/filing/0001193125-26-089282#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10539.0,"shares_display":"10,539","price_per_share":22.8,"price_display":"22.80","price_state":"stated","total_value":240289.2,"total_display":"240,289.20","total_whole":"240,289","shares_owned_after":89515.0,"shares_owned_after_display":"89,515","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-02","filed_date":"2026-03-03","scope":"insider"},{"id":4834686,"accession":"0000950170-25-032773","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-032773","line_url":"/filing/0000950170-25-032773#line-3","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15103.0,"shares_display":"15,103","price_per_share":42.1,"price_display":"42.10","price_state":"stated","total_value":635836.3,"total_display":"635,836.30","total_whole":"635,836","shares_owned_after":87855.0,"shares_owned_after_display":"87,855","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-03","filed_date":"2025-03-04","scope":"insider"},{"id":2513817,"accession":"0000950170-24-026629","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-026629","line_url":"/filing/0000950170-24-026629#line-3","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4768.0,"shares_display":"4,768","price_per_share":53.76,"price_display":"53.76","price_state":"stated","total_value":256327.68,"total_display":"256,327.68","total_whole":"256,328","shares_owned_after":67163.0,"shares_owned_after_display":"67,163","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-01","filed_date":"2024-03-05","scope":"insider"},{"id":8657921,"accession":"0001209191-23-048491","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-048491","line_url":"/filing/0001209191-23-048491#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6000.0,"shares_display":"6,000","price_per_share":37.96,"price_display":"37.96","price_state":"stated","total_value":227760.0,"total_display":"227,760.00","total_whole":"227,760","shares_owned_after":51281.0,"shares_owned_after_display":"51,281","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-05","filed_date":"2023-09-06","scope":"insider"},{"id":8254324,"accession":"0001209191-23-038885","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-038885","line_url":"/filing/0001209191-23-038885#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":305.0,"shares_display":"305","price_per_share":48.2,"price_display":"48.20","price_state":"stated","total_value":14701.0,"total_display":"14,701.00","total_whole":"14,701","shares_owned_after":57281.0,"shares_owned_after_display":"57,281","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-19","filed_date":"2023-06-21","scope":"insider"},{"id":7810339,"accession":"0001209191-23-016039","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-016039","line_url":"/filing/0001209191-23-016039#line-3","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3664.0,"shares_display":"3,664","price_per_share":45.25,"price_display":"45.25","price_state":"stated","total_value":165796.0,"total_display":"165,796.00","total_whole":"165,796","shares_owned_after":57344.0,"shares_owned_after_display":"57,344","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-01","filed_date":"2023-03-03","scope":"insider"},{"id":6148831,"accession":"0001209191-22-038774","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-038774","line_url":"/filing/0001209191-22-038774#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":295.0,"shares_display":"295","price_per_share":54.78,"price_display":"54.78","price_state":"stated","total_value":16160.1,"total_display":"16,160.10","total_whole":"16,160","shares_owned_after":36160.0,"shares_owned_after_display":"36,160","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-19","filed_date":"2022-06-22","scope":"insider"},{"id":6652093,"accession":"0001209191-22-015830","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-015830","line_url":"/filing/0001209191-22-015830#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2713.0,"shares_display":"2,713","price_per_share":66.62,"price_display":"66.62","price_state":"stated","total_value":180740.06,"total_display":"180,740.06","total_whole":"180,740","shares_owned_after":22317.0,"shares_owned_after_display":"22,317","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-01","filed_date":"2022-03-03","scope":"insider"},{"id":4237038,"accession":"0001209191-21-060760","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-060760","line_url":"/filing/0001209191-21-060760#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":303.0,"shares_display":"303","price_per_share":81.14,"price_display":"81.14","price_state":"stated","total_value":24585.42,"total_display":"24,585.42","total_whole":"24,585","shares_owned_after":25030.0,"shares_owned_after_display":"25,030","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-14","filed_date":"2021-10-18","scope":"insider"},{"id":5101748,"accession":"0001209191-21-045972","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-045972","line_url":"/filing/0001209191-21-045972#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":375.0,"shares_display":"375","price_per_share":91.53,"price_display":"91.53","price_state":"stated","total_value":34323.75,"total_display":"34,323.75","total_whole":"34,324","shares_owned_after":25333.0,"shares_owned_after_display":"25,333","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-06","filed_date":"2021-07-08","scope":"insider"},{"id":4838062,"accession":"0001209191-21-042812","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-042812","line_url":"/filing/0001209191-21-042812#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":572.0,"shares_display":"572","price_per_share":94.96,"price_display":"94.96","price_state":"stated","total_value":54317.12,"total_display":"54,317.12","total_whole":"54,317","shares_owned_after":25708.0,"shares_owned_after_display":"25,708","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-21","filed_date":"2021-06-23","scope":"insider"},{"id":4838055,"accession":"0001209191-21-042812","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-042812","line_url":"/filing/0001209191-21-042812#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":437.0,"shares_display":"437","price_per_share":94.63,"price_display":"94.63","price_state":"stated","total_value":41353.31,"total_display":"41,353.31","total_whole":"41,353","shares_owned_after":26280.0,"shares_owned_after_display":"26,280","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-19","filed_date":"2021-06-23","scope":"insider"},{"id":5159974,"accession":"0001209191-21-031378","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-031378","line_url":"/filing/0001209191-21-031378#line-2","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":393.0,"shares_display":"393","price_per_share":113.67,"price_display":"113.67","price_state":"stated","total_value":44672.31,"total_display":"44,672.31","total_whole":"44,672","shares_owned_after":26717.0,"shares_owned_after_display":"26,717","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-07","filed_date":"2021-05-10","scope":"insider"},{"id":5159965,"accession":"0001209191-21-031378","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-031378","line_url":"/filing/0001209191-21-031378#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":307.0,"shares_display":"307","price_per_share":113.68,"price_display":"113.68","price_state":"stated","total_value":34899.76,"total_display":"34,899.76","total_whole":"34,900","shares_owned_after":27110.0,"shares_owned_after_display":"27,110","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-06","filed_date":"2021-05-10","scope":"insider"},{"id":4423873,"accession":"0001209191-21-027881","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-027881","line_url":"/filing/0001209191-21-027881#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":396.0,"shares_display":"396","price_per_share":104.28,"price_display":"104.28","price_state":"stated","total_value":41294.88,"total_display":"41,294.88","total_whole":"41,295","shares_owned_after":27417.0,"shares_owned_after_display":"27,417","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-20","filed_date":"2021-04-21","scope":"insider"},{"id":5037022,"accession":"0001209191-21-017554","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-017554","line_url":"/filing/0001209191-21-017554#line-4","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":707.0,"shares_display":"707","price_per_share":138.16,"price_display":"138.16","price_state":"stated","total_value":97679.12,"total_display":"97,679.12","total_whole":"97,679","shares_owned_after":27813.0,"shares_owned_after_display":"27,813","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-02","filed_date":"2021-03-03","scope":"insider"},{"id":5037016,"accession":"0001209191-21-017554","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-017554","line_url":"/filing/0001209191-21-017554#line-3","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2470.0,"shares_display":"2,470","price_per_share":138.17,"price_display":"138.17","price_state":"stated","total_value":341279.9,"total_display":"341,279.90","total_whole":"341,280","shares_owned_after":28520.0,"shares_owned_after_display":"28,520","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-01","filed_date":"2021-03-03","scope":"insider"},{"id":2294587,"accession":"0001209191-20-055176","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-055176","line_url":"/filing/0001209191-20-055176#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":220.0,"shares_display":"220","price_per_share":88.0,"price_display":"88.00","price_state":"stated","total_value":19360.0,"total_display":"19,360.00","total_whole":"19,360","shares_owned_after":23370.0,"shares_owned_after_display":"23,370","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-14","filed_date":"2020-10-16","scope":"insider"},{"id":5144569,"accession":"0001209191-21-007555","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-007555","line_url":"/filing/0001209191-21-007555#line-1","is_derivative":false,"issuer_cik":"0001515673","issuer_name":"Ultragenyx Pharmaceutical Inc.","issuer_ticker":"RARE","issuer_name_source":null,"issuer_url":"/issuer/0001515673","owner_cik":"0001780113","owner_name":"Harris Erik","owner_display_name":"Harris Erik","owner_url":"/insider/0001780113","role":"Officer (EVP & Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (EVP & Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP & Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2516.0,"shares_display":"2,516","price_per_share":74.69,"price_display":"74.69","price_state":"stated","total_value":187920.04,"total_display":"187,920.04","total_whole":"187,920","shares_owned_after":20854.0,"shares_owned_after_display":"20,854","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-06-03","filed_date":"2021-02-03","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":19,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":19,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":19},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001515673","name":"Ultragenyx Pharmaceutical Inc.","url":"/issuer/0001515673","role":"Officer (EVP & Chief Commercial Officer)","n_filings":16,"first_seen":"2020-10-16","last_seen":"2026-03-03"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001780113","retrieved_at":"2026-08-23T12:55:04+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}